{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:18:08Z","timestamp":1782184688756,"version":"3.54.5"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Japanese Radiation Oncology Study Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Palliative radiotherapy is the standard of care for bone metastases. However, skeletal-related events, defined as a pathologic fracture, paraplegia, surgery or radiotherapy for local recurrence, or severe pain in previously irradiated bone with radio-resistant histology type still present high incidence. The primary objective of this study was to determine whether zoledronic acid hydrate and palliative radiotherapy could prevent local skeletal-related events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients with bone metastases from renal cell carcinoma were treated with zoledronic acid hydrate every 3 or 4\u00a0weeks and concurrent palliative radiotherapy of 30\u00a0Gy in 3\u00a0Gy fractions. The criteria for radiotherapy were established by the treating physician, but patients with complicated bone metastases (impending pathological fracture or spinal cord compression) which needed immediate surgery were excluded. The primary endpoint was the local skeletal-related event-free survival rate at 1\u00a0year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-seven patients were included in the study. The median age was 65 (range, 50\u201384) years. Radiotherapy dose was 30\u00a0Gy for all patients except 1 whose radiotherapy was terminated due to brain metastasis progression at 18\u00a0Gy. Zoledronic acid hydrate was administered in a median of 12 (range, 0\u201334) times. The median follow-up period was 12\u00a0months and 19\u00a0months in patients who were still alive. Of 27 patients in the efficacy analysis, the 1-year local skeletal-related event-free rate was 77.6% (80% confidence interval, 66.2\u201389.0). Common grade 3 toxicities were hypocalcemia (1 [4%]), sGPT level increase (1 [4%]) and sGOT level increase (1 [4%]). There was no grade 4 or 5 toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Zoledronic acid hydrate administration and palliative radiotherapy were a well-tolerated and promising treatment reducing skeletal-related events for bone metastases from renal cell carcinoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa158","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T03:44:55Z","timestamp":1598586295000},"page":"100-105","source":"Crossref","is-referenced-by-count":7,"title":["A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma"],"prefix":"10.1093","volume":"51","author":[{"given":"Hideyuki","family":"Harada","sequence":"first","affiliation":[{"name":"Division of Radiation Therapy, Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Shikama","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobue","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tottori University, Tottori, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Dokkyo Medical Unversity, Saitama Medical Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Kanagawa, Japan"},{"name":"Department of Radiation Oncology, NHO Disaster Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Seirei Mikatahara General Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayasu","family":"Nagakura","sequence":"additional","affiliation":[{"name":"Department of Radiology, KKR Sapporo Medical Center, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Radiation Therapy, Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Showa General Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Katagiri","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Oncology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2020122723595868700_ref1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/00365599209181227","article-title":"Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma","volume":"26","author":"Henriksson","year":"1992","journal-title":"Scand J Urol Nephrol"},{"key":"2020122723595868700_ref2","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int J Oncol"},{"key":"2020122723595868700_ref3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1442-2042.2010.02468.x","article-title":"Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan","volume":"17","author":"Yokomizo","year":"2010","journal-title":"Int J Urol"},{"key":"2020122723595868700_ref4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0360-3016(98)00288-0","article-title":"Clinical results of nonsurgical treatment for spinal metastases","volume":"42","author":"Katagiri","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020122723595868700_ref5","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic acid lung cancer and other solid Tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"2020122723595868700_ref6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1464-410X.2008.08124.x","article-title":"Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate","volume":"103","author":"Kijima","year":"2008","journal-title":"BJU"},{"key":"2020122723595868700_ref7","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","article-title":"Et al","volume":"82","author":"Chow","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020122723595868700_ref8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline version 1.19","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2020122723595868700_ref9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/cam4.292","article-title":"New prognostic factors and scoring system for patients with skeletal metastasis","volume":"3","author":"Katagiri","year":"2014","journal-title":"Cancer Med"},{"key":"2020122723595868700_ref10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/theoncologist.2012-0293","article-title":"The NOMS framework: approach to the treatment of spinal metastatic Tumors","volume":"18","author":"Laufer","year":"2013","journal-title":"Oncologist"},{"key":"2020122723595868700_ref11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10147-018-1310-7","article-title":"Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis","volume":"23","author":"Hosaka","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2020122723595868700_ref12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijrobp.2009.12.038","article-title":"Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases","volume":"79","author":"Greco","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020122723595868700_ref13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jrr\/rrv083","article-title":"Reirradiation of spinal metastases with intensity-modulated radiation therapy: an analysis of 23 patients","volume":"57","author":"Kawashiro","year":"2016","journal-title":"J Radiat Res"},{"key":"2020122723595868700_ref14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.urolonc.2010.02.006","article-title":"Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer","volume":"30","author":"Staehler","year":"2012","journal-title":"Urol Oncol"},{"key":"2020122723595868700_ref15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10456-015-9476-3","article-title":"Combining radiotherapy with sunitinib: lessons (to be) learned","volume":"18","author":"Kleibeuker","year":"2015","journal-title":"Angiogenesis"},{"key":"2020122723595868700_ref16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/1\/100\/35141698\/hyaa158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/1\/100\/35141698\/hyaa158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T05:00:30Z","timestamp":1609131630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/1\/100\/5899737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa158","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,9,1]]}}}